Abstract: The glycinamide of the formula is reacted with the dioxolane of the formula wherein L is a leaving group such as iodo, bromo, alkylsulfonyloxy, or arylsulfonyloxy to give the dioxolane of the formula Treating the dioxolane of formula III under aqueous refluxing conditions followed by exchanging the dioxolane acetal with a dimethoxy acetal and introduction of the methyl ester gives (S)-2-amino-6,6-dimethoxyhexanoic acid, methyl ester which is an intermediate in the preparation of the dual inhibitor [4S-[4&agr;(R*),7&agr;,10a&bgr;]]-octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)-amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid. Also disclosed are storage stable salts of (S)-2-amino-6, 6-dimethoxyhexanoic acid, methyl ester.

Abstract: The glycinamide of the formula is reacted with the dioxolane of the formula wherein L is a leaving group such as iodo, bromo, alkylsulfonyloxy, or arylsulfonyloxy to give the dioxolane of the formula Treating the dioxolane of formula III under aqueous refluxing conditions followed by exchanging the dioxolane acetal with a dimethoxy acetal and introduction of the methyl ester gives (S)-2-amino-6,6-dimethoxyhexanoic acid, methyl ester which is an intermediate in the preparation of the dual inhibitor [4S-[4&agr;(R*),7&agr;, 10a&bgr;]]-)octahydro-4-[(2-mercapto-1-oxo-3-phenylpropy)-amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid. Also disclosed are storage stable salts of (S)-2-amino-6,6-dimethoxyhexanoic acid, methyl ester.

Abstract: A process for the synthesis of paclitaxel from 10-deacetylbaccatin-III which is protected at the 7-position with a dialkylalkoxysilyl protecting group having the formula —Si(R)2(OR′).

Abstract: Disclosed are crystalline complexes of baccatin III with imidazole, 2-methylimidazole or isopropanol, which are useful for isolating baccatin III from plant tissue cell culture and plant extracts containing baccatin Ill.

Abstract: N-protected-L-homocysteine disulfide of the formula ##STR1## or an activated form thereof is reacted with (S)-2-amino-6,6-dimethoxyhexanoic acid, methyl ester to give the disulfide intermediate of the formula ##STR2## Cleavage of the disulfide bond followed by acid catalyzed cyclization produces the N-protected lactam of formula III which is useful for preparing the pharmaceutically active compound omapatrilat.

Abstract: Etoposide phosphate is prepared by coupling dibenzyl 4'-demethyl-4-epipodophyllotoxin-4'-phosphate with 2,3-di-O-benzyl-4,6-O-ethylidene-.alpha.,.beta.-D-glucopyranose in a solvent and subsequently removing the protecting groups. The tetra-benzyl protected etoposide phosphate is recrystallized from methanol or directly crystallized from acetonitrile by adding methanol to yield substantially the pure C-1"-.beta. form. The benzyl protecting groups are simultaneously removed by hydrogenation to produce etoposide phosphate in high yields. In a further embodiment, etoposide phosphate is treated with a phosphatase enzyme to yield etoposide.

Abstract: The present invention is an improvement to a process for the conversion of natural gas to produce higher molecular weight hydrocarbon products, wherein the natural gas is partially oxidized to produce a synthesis gas comprising carbon monoxide and hydrogen, wherein the synthesis gas is catalytically reacted to produce the higher molecular weight hydrocarbon products, wherein the conversion process generates excess steam and wherein oxygen used to partially oxidize the natural gas is produced by an air separation process. The improvement is characterized by operating such air separation process at an elevated pressure so that the feed air to the air separation process is compressed to between 8 and 20 Bar(a); expanding at least a portion of the excess steam generated by the conversion process to generate work and using at least a portion of the generated work to drive the compression requirements of the air separation process.

Abstract: Etoposide phosphate is prepared by coupling dibenzyl 4'-demethyl-4-epipodophyllotoxin-4'-phosphate with 2,3-di-O-benzyl-4,6-O-ethylidene-.alpha.,.beta.-D-glucopyranose in a solvent and subsequently removing the protecting groups. The tetra-benzyl protected etoposide phosphate is recrystallized from methanol or directly crystallized from acetonitrile by adding methanol to yield substantially the pure C-1"-.beta. form. The benzyl protecting groups are simultaneously removed by hydrogenation to produce etoposide phosphate in high yields. In a further embodiment, etoposide phosphate is treated with a phosphatase enzyme to yield etoposide.

Abstract: Garments are constructed from two identical sleeve sections folded and joined to form an upper portion, which has a neck opening and sleeves, joined to a rectangular lower portion, which forms the body portion of the garment. The upper portion and the lower portion are joined together by a straight circumferential seam. The sleeve sections and the lateral edges of the lower portion are joined by a straight vertical seam. Preferably, the sleeve sections are folded so as to be overlapped and form a neck opening that is V-shaped. In a most preferred embodiment, the garment of the present invention is a scrub shirt. The present invention makes use of sleeve sections that are in the shape of quadrilateral sections with an arcuate portion cut therefrom. The patterns disclosed make efficient use of the material from which they are cut and require only straight seams when assembled. The present invention also discloses methods of constructing garments, such as scrub shirts, in accordance with the disclosed design.

Abstract: In order to maximize protection against bacteria, this medical garment includes a double front. The medical garment includes a sleeve portion having first and second main sleeves extending continuously from the neck opening to an outer edge thereof. A first body portion of the garment has a first front panel extending continuously from the neck portion downwardly to a first bottom edge thereof, and a rear panel extending from the neck opening to the first bottom. A second body portion is secured to the rear panel and has a second front panel overlying the first front panel to provide the aforementioned double-layered front form the garment. The second front panel runs continuously from the neck opening to a second bottom edge thereof which is not attached to the first front panel such that an open passageway is formed between the first and second front panels to provide an added protective air space layer.

Abstract: A novel dimethylsulfate quaternary salt process intermediate useful in the manufacture of the antiarrhythmic agent encainide.

Abstract: A new and novel process for the preparation of encainide (4-methoxy-2'-[2-(1-methyl-2-piperidyl)ethyl]-benzanilide) has been developed. The process utilizes .alpha.-picoline, O-nitrobenzaldehyde, and anisoyl chloride as starting materials.